(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 23 December 2004 (23.12.2004)

(10) International Publication Number WO 2004/110487 A1

A61K 39/395, (51) International Patent Classification7: 38/16, 48/00

(21) International Application Number:

PCT/IL2004/000528

(22) International Filing Date: 17 June 2004 (17.06.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

156495 60/490,961

17 June 2003 (17.06.2003) 30 July 2003 (30.07.2003)

(71) Applicant (for all designated States except US): PRO-CHON BIOTECH LTD. [IL/IL]; P.O. Box 1482, 76114 Rehovot (IL).

(72) Inventor; and

(75) Inventor/Applicant (for US only): YAYON, Avner [IL/IL]; Sitria 104, 76834 Moshav Sitria (IL).

(74) Agent: WEBB, Cynthia; Webb & Associates, P.O. Box 2189, 76121 Rehovot (IL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE. AG. AL, AM. AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM. TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO. SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ. GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TREATMENT OF T CELL MEDIATED DISEASES BY INHIBITION OF FGFR3

(57) Abstract: The present invention provides a method of preventing and treating a T cell mediated disease, including inflammatory autoimmune diseases and in particular rheumatoid arthritis, by administering to an individual in need thereof at least one FGFR 3 inhibitor including a molecule comprising the antigen-binding portion of an antibody having a specific affinity for fibroblast growth factor receptor 3 (FGFR3), a FGFR3 : pecific small organic molecule tyrosine kinase inhibitor, a FGFR3 specific soluble receptor, a FGFR3 peptide or peptidomimetic, a FGFR3 specific RNA inhibitor, a FGFR3 specific antogonist ligand or a DNA vaccine encoding FGFR3 or a fragment thereof, or an inhibitor of heparan sulfate binding.

